[Non-viral sexually transmitted infections - Epidemiology, clinical manifestations, diagnostics and therapy : Part 2:...

Area of Science:

• Microbiology
• Infectious Diseases
• Public Health

Background:

• Chlamydia trachomatis is the leading cause of bacterial sexually transmitted infections globally, with an estimated 300,000 new cases annually in Germany.
• Infections primarily affect individuals aged 15-25 and are often asymptomatic, necessitating screening or diagnosis upon complication.
• Genital Mycoplasma species, including Ureaplasma urealyticum, Ureaplasma parvum, Mycoplasma hominis, and Mycoplasma genitalium, are also significant causes of genitourinary infections.

Purpose of the Study:

• To summarize current knowledge on the diagnosis and treatment of Chlamydia trachomatis and genital Mycoplasma infections.
• To highlight the importance of partner treatment and molecular diagnostic techniques for Mycoplasma genitalium.

Main Methods:

• Review of diagnostic and treatment guidelines for Chlamydia trachomatis and genital Mycoplasma.
• Description of diagnostic methods including nucleic acid amplification techniques (NAAT) and PCR.
• Outline of recommended antibiotic therapies for various Mycoplasma species.

Main Results:

• Chlamydia trachomatis infections are typically treated with doxycycline or azithromycin, with partner management being crucial.
• Mycoplasma genitalium, a newly identified species, requires specific molecular diagnosis (PCR) and treatment with azithromycin.
• Ureaplasma infections respond to doxycycline or clarithromycin, while Mycoplasma hominis may require clindamycin if doxycycline is ineffective.

Conclusions:

• Effective management of Chlamydia and Mycoplasma infections relies on accurate diagnosis and appropriate antibiotic selection.
• Screening and prompt treatment are essential to prevent complications and control the spread of these common STIs.
• Molecular diagnostics are increasingly important for identifying specific Mycoplasma species and guiding therapy.